SG11201911313YA - Modulators of alpha-synuclein - Google Patents
Modulators of alpha-synucleinInfo
- Publication number
- SG11201911313YA SG11201911313YA SG11201911313YA SG11201911313YA SG11201911313YA SG 11201911313Y A SG11201911313Y A SG 11201911313YA SG 11201911313Y A SG11201911313Y A SG 11201911313YA SG 11201911313Y A SG11201911313Y A SG 11201911313YA SG 11201911313Y A SG11201911313Y A SG 11201911313YA
- Authority
- SG
- Singapore
- Prior art keywords
- synuclein
- modulators
- alpha
- Prior art date
Links
- 102000003802 alpha-Synuclein Human genes 0.000 title 1
- 108090000185 alpha-Synuclein Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Amplifiers (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762521758P | 2017-06-19 | 2017-06-19 | |
PCT/IB2018/000766 WO2018234864A2 (fr) | 2017-06-19 | 2018-06-19 | Modulateurs d'alpha-synucléine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201911313YA true SG11201911313YA (en) | 2020-01-30 |
Family
ID=64736960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201911313YA SG11201911313YA (en) | 2017-06-19 | 2018-06-19 | Modulators of alpha-synuclein |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200206191A1 (fr) |
EP (1) | EP3641761A4 (fr) |
JP (2) | JP2020524667A (fr) |
KR (1) | KR20200010487A (fr) |
CN (1) | CN110891565A (fr) |
AU (1) | AU2018287319A1 (fr) |
BR (1) | BR112019027029A2 (fr) |
CA (1) | CA3067135A1 (fr) |
IL (1) | IL271359B2 (fr) |
MX (1) | MX2019015273A (fr) |
SG (1) | SG11201911313YA (fr) |
WO (1) | WO2018234864A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102150377B1 (ko) * | 2020-03-26 | 2020-09-01 | 서울대학교산학협력단 | 플루오린-18이 치환된 피라졸 유도체 방사성의약품 제조방법 |
EP4206200A1 (fr) * | 2020-08-25 | 2023-07-05 | National Institutes for Quantum Science and Technology | Nouveau composé, liant pour agrégat d'alpha-synucléine et utilisation associée |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0203446D0 (en) * | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
KR100832747B1 (ko) * | 2006-10-27 | 2008-05-27 | 한국화학연구원 | 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물 |
ES2392862B1 (es) * | 2011-06-02 | 2013-11-05 | Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal | Tgf-beta y/o smad3 como marcadores de diagnóstico y/o pronóstico de alfa-sinucleinopatías |
US20160007893A1 (en) * | 2013-02-06 | 2016-01-14 | Loxbridge Research Llp | Systems and methods for early disease detection and real-time disease monitoring |
TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
WO2019152546A2 (fr) * | 2018-01-30 | 2019-08-08 | Kainos Medicine Inc. | Formes salines de composé organique |
-
2018
- 2018-06-19 IL IL271359A patent/IL271359B2/en unknown
- 2018-06-19 CN CN201880040954.1A patent/CN110891565A/zh active Pending
- 2018-06-19 KR KR1020197038067A patent/KR20200010487A/ko not_active Application Discontinuation
- 2018-06-19 JP JP2019569256A patent/JP2020524667A/ja active Pending
- 2018-06-19 US US16/622,138 patent/US20200206191A1/en active Pending
- 2018-06-19 WO PCT/IB2018/000766 patent/WO2018234864A2/fr active Search and Examination
- 2018-06-19 MX MX2019015273A patent/MX2019015273A/es unknown
- 2018-06-19 AU AU2018287319A patent/AU2018287319A1/en active Pending
- 2018-06-19 EP EP18820452.3A patent/EP3641761A4/fr active Pending
- 2018-06-19 SG SG11201911313YA patent/SG11201911313YA/en unknown
- 2018-06-19 BR BR112019027029-9A patent/BR112019027029A2/pt active Search and Examination
- 2018-06-19 CA CA3067135A patent/CA3067135A1/fr active Pending
-
2023
- 2023-07-06 JP JP2023111393A patent/JP2023118923A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3067135A1 (fr) | 2018-12-27 |
JP2020524667A (ja) | 2020-08-20 |
MX2019015273A (es) | 2020-08-17 |
IL271359B2 (en) | 2023-11-01 |
US20200206191A1 (en) | 2020-07-02 |
KR20200010487A (ko) | 2020-01-30 |
WO2018234864A3 (fr) | 2019-02-14 |
IL271359B1 (en) | 2023-07-01 |
IL271359A (en) | 2020-01-30 |
EP3641761A4 (fr) | 2021-03-24 |
AU2018287319A1 (en) | 2020-02-06 |
RU2020101482A (ru) | 2021-07-20 |
WO2018234864A2 (fr) | 2018-12-27 |
RU2020101482A3 (fr) | 2022-01-31 |
EP3641761A2 (fr) | 2020-04-29 |
JP2023118923A (ja) | 2023-08-25 |
CN110891565A (zh) | 2020-03-17 |
BR112019027029A2 (pt) | 2020-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283582A (en) | ror - gamma modulators | |
HK1256599A1 (zh) | ROR-γ的調節劑 | |
HK1250999A1 (zh) | Ror1-ror2結合的調節劑 | |
IL259342B (en) | Modulators of chemokine receptors | |
HK1251486A1 (zh) | Sestrin-gator2相互作用的調節劑和其用途 | |
PL3743406T3 (pl) | Modulatory tmem16a | |
IL281492A (en) | Modulators of PNPLA3 expression | |
IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
PL3303291T3 (pl) | Modulatory ROR-gamma | |
GB2594008B (en) | Modulators | |
PL3303293T3 (pl) | Modulatory ROR-gamma | |
PL3303290T3 (pl) | Modulatory ROR-gamma | |
IL283967A (en) | Modulators of hsd17b13 expression | |
GB201716468D0 (en) | Modulators | |
PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORγ) | |
IL304618A (en) | Modulators of pcsk9 expression | |
IL266261A (en) | ror-gamma modulators | |
IL271359A (en) | Modulators of alpha-synuclein | |
IL274231A (en) | Modulators of ENAC expression | |
GB2585587B (en) | Modulators | |
GB2563095B (en) | Modulators | |
IL271332B (en) | Tetrahydropyridopyrazine modulators of gpr6 | |
GB201702926D0 (en) | Modulators | |
GB201721386D0 (en) | Chrondogy of time-wave |